*1.Please list your first name, last name, and email:(Required.)

First name:

Last name:

Email:

*2.What is your specialty?(Required.)

*3.Why are pNETs more inherently sensitive to alkylating agents (CAPTEM) vs other NETs?(Required.)

High percent of MGMT loss

High percent of BRCA/PALB2/ATM mutation

pNETs are not chemosens

High percent of MMR deficiency

*4.Which therapy is approved by the FDA for the treatment of MSS TMB low pNETs irrespective of SSTR expression?(Required.)

Pembrolizumab

Nivolumab + ipilimumab

Everolimus

Peptide receptor radionuclide therapy (PRRT) with lutetium dotatate